BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 6605844)

  • 1. [Chemotherapy of cutaneous T-cell lymphomas with arotinoid].
    Mahrle G; Thiele B; Ippen H
    Dtsch Med Wochenschr; 1983 Nov; 108(46):1753-7. PubMed ID: 6605844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of cutaneous T-cell lymphomas with TP-5. Evaluation of the clinical effect in 8 patients.
    Przybilla B; Burg G; Schmoeckel C; Braun-Falco O
    Acta Derm Venereol; 1983; 63(6):524-9. PubMed ID: 6198843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of cutaneous T-cell lymphoma with the arotinoid Ro 13-6298.
    Tousignant J; Raymond GP; Light MJ
    J Am Acad Dermatol; 1987 Jan; 16(1 Pt 2):167-71. PubMed ID: 3493269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides).
    Kessler JF; Jones SE; Levine N; Lynch PJ; Booth AR; Meyskens FL
    Arch Dermatol; 1987 Feb; 123(2):201-4. PubMed ID: 2949706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients.
    Bouwhuis SA; Davis MD; el-Azhary RA; McEvoy MT; Gibson LE; Knudsen JM; Kist JM; Pittelkow MR
    J Am Acad Dermatol; 2005 Jun; 52(6):991-6. PubMed ID: 15928617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applying the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome in primary cutaneous marginal zone lymphoma.
    Gerami P; Wickless SC; Rosen S; Kuzel TM; Ciurea A; Havey J; Guitart J
    J Am Acad Dermatol; 2008 Aug; 59(2):245-54. PubMed ID: 18486274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. State of the art therapy of mycosis fungoides and Sézary syndrome.
    Kemme DJ; Bunn PA
    Oncology (Williston Park); 1992 Feb; 6(2):31-42; discussion 44, 47-8. PubMed ID: 1532501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma.
    Marolleau JP; Baccard M; Flageul B; Rybojad M; Laroche L; Vérola O; Brandely M; Morel P; Gisselbrecht C
    Arch Dermatol; 1995 May; 131(5):574-9. PubMed ID: 7741545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bexarotene therapy for mycosis fungoides and Sézary syndrome.
    Abbott RA; Whittaker SJ; Morris SL; Russell-Jones R; Hung T; Bashir SJ; Scarisbrick JJ
    Br J Dermatol; 2009 Jun; 160(6):1299-307. PubMed ID: 19222457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral retinoids in mycosis fungoides and Sézary syndrome: a comparison of isotretinoin and etretinate. A study from the Scandinavian Mycosis Fungoides Group.
    Molin L; Thomsen K; Volden G; Aronsson A; Hammar H; Hellbe L; Wantzin GL; Roupe G
    Acta Derm Venereol; 1987; 67(3):232-6. PubMed ID: 2442936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Diagnosis and therapy of cutaneous T-cell lymphomas].
    Le T; Pierard GE; Pierard-Franchimont C; de la Brassinne M; Lapière CM
    Dermatologica; 1984; 169(2):60-5. PubMed ID: 6332749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma.
    Whittaker SJ; Foss FM
    Cancer Treat Rev; 2007 Apr; 33(2):146-60. PubMed ID: 17275192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 13-cis-retinoic acid effective in mycosis fungoides. A report from the Scandinavian Mycosis Fungoides Group.
    Thomsen K; Molin L; Volden G; Lange Wantzin G; Hellbe L
    Acta Derm Venereol; 1984; 64(6):563-6. PubMed ID: 6084938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non lymphoblastic T cell lymphomas with prevalent skin involvement different from mycosis fungoides or Sézary's syndrome. A retrospective study of 6 cases in Europe.
    Grob JJ; Horchowski N; Tubiana N; Gabriel B; Gastaut JA; Hassoun J; Jouve I; Carcassone Y; Bonerandi JJ
    Dermatologica; 1988; 177(2):82-97. PubMed ID: 3262542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pentostatin (Nipent) in T-cell malignancies. Leukemia Cooperative Group and the European Organization for Research and Treatment of Cancer.
    Ho AD; Suciu S; Stryckmans P; De Cataldo F; Willemze R; Thaler J; Peetermans M; Döhner H; Solbu G; Dardenne M; Zittoun R
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):52-7. PubMed ID: 10877053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of advanced mycosis fungoides and Sézary syndrome with continuous infusions of methotrexate followed by fluorouracil and leucovorin rescue.
    Schappell DL; Alper JC; McDonald CJ
    Arch Dermatol; 1995 Mar; 131(3):307-13. PubMed ID: 7887660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pentostatin treatment of cutaneous T-cell lymphoma.
    Dearden C; Matutes E; Catovsky D
    Oncology (Williston Park); 2000 Jun; 14(6 Suppl 2):37-40. PubMed ID: 10887643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of retinoids and PUVA (Re-PUVA) in the treatment of cutaneous T cell lymphomas.
    Serri F; De Simone C; Venier A; Rusciani L; Marchetti F
    Curr Probl Dermatol; 1990; 19():252-7. PubMed ID: 2404681
    [No Abstract]   [Full Text] [Related]  

  • 19. O6-alkylguanine-DNA alkyltransferase in cutaneous T-cell lymphoma: implications for treatment with alkylating agents.
    Dolan ME; McRae BL; Ferries-Rowe E; Belanich M; van Seventer GA; Guitart J; Pezen D; Kuzel TM; Yarosh DB
    Clin Cancer Res; 1999 Aug; 5(8):2059-64. PubMed ID: 10473086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas.
    Vermeer MH; Tensen CP; van der Stoop PM; van Oostveen HW; Lund M; Scheper RJ; Willemze R
    Arch Dermatol; 2001 Jul; 137(7):901-5. PubMed ID: 11453809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.